Document is current
Any future updates will be listed below
-
Authors
Scahill, Rachael I.
Farag, Mena https://orcid.org/0000-0002-0679-0117
Murphy, Michael J.
Hobbs, Nicola Z.
Leocadi, Michela
Langley, Christelle https://orcid.org/0000-0001-5061-2820
Knights, Harry
Ciosi, Marc https://orcid.org/0000-0002-7663-4080
Fayer, Kate
Nakajima, Mitsuko
Thackeray, Olivia
Gobom, Johan https://orcid.org/0000-0001-6193-6193
Rönnholm, John
Weiner, Sophia https://orcid.org/0009-0000-2298-220X
Hassan, Yara R.
Ponraj, Nehaa K. P. https://orcid.org/0009-0002-9576-5753
Estevez-Fraga, Carlos https://orcid.org/0000-0001-6855-1093
Parker, Christopher S.
Malone, Ian B.
Hyare, Harpreet
Long, Jeffrey D. https://orcid.org/0000-0001-7181-9652
Heslegrave, Amanda
Sampaio, Cristina https://orcid.org/0000-0002-7052-9079
Zhang, Hui https://orcid.org/0000-0002-5426-2140
Robbins, Trevor W. https://orcid.org/0000-0003-0642-5977
Zetterberg, Henrik
Wild, Edward J. https://orcid.org/0000-0002-6921-7887
Rees, Geraint https://orcid.org/0000-0002-9623-7007
Rowe, James B. https://orcid.org/0000-0001-7216-8679
Sahakian, Barbara J. https://orcid.org/0000-0001-7352-1745
Monckton, Darren G. https://orcid.org/0000-0002-8298-8264
Langbehn, Douglas R.
Tabrizi, Sarah J. https://orcid.org/0000-0003-2716-2045
-
Funding
Funding for this research was provided by:
Wellcome Trust (223082/Z/21/Z, 223082/Z/21/Z, 223082/Z/21/Z, 223082/Z/21/Z, 223082/Z/21/Z, 223082/Z/21/Z, 223082/Z/21/Z, 223082/Z/21/Z, 223082/Z/21/Z, 223082/Z/21/Z)
CHDI Foundation
- License Information
-
More Information
Article History
Received: 2 August 2024
Accepted: 15 November 2024
First Online: 17 January 2025
Competing interests
: J.B.R. is supported by the Wellcome Trust (220258), the Medical Research Council (MC_UU_00030/14; MR/T033371/1) and the NIHR Cambridge Biomedical Research Centre (NIHR203312). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. J.B.R. has undertaken paid consultancy for Asceneuron, Astronautx, Astex, ClinicalInk, CumulusNeuro, Curasen, Invivro, Prevail and SVHealth; received research funding unrelated to the current work from AstraZeneca, Lily, GSK and Janssen; and is Chief Scientific Advisor to Alzheimer’s Research UK. D.G.M. has been a scientific consultant and/or received honoraria/grants from AMO Pharma, Dyne, F. Hoffman-La Roche, Function Rx, LoQus23, MOMA Therapeutics, Novartis, Ono Pharmaceuticals, Pfizer Pharmaceuticals, Rgenta Therapeutics, Sanofi and Sarepta Therapeutics. J.G. is supported by Alzheimerfonden (AF-980746) and Stiftelsen för Gamla tjänarinnor (2022-01324). J.B.R. has appeared as an expert witness to the Medicines and Healthcare products Regulatory Agency, unrelated to the current work. D.G.M. is on the Scientific Advisory Board of the Myotonic Dystrophy Foundation and EuroDyMA (European Dystrophia Myotonica Association), is a scientific advisor to the Myotonic Dystrophy Support Group and is a vice president for research of Muscular Dystrophy UK. G.R. is a nonexecutive director of UCL Business. D.R.L. is an unpaid academic member of the Critical Path Institute HD-RSC Consortium Coordinating Committee. B.J.S. is a co-inventor of the Cambridge Neuropsychological Test Automated Battery. I.B.M. is an associate editor for Frontiers in Neurology. The other authors declare no competing interests.
